{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"groups":[{"description":"Mezagitamab, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons. TAK-079 dose for this phase was to be determined based on review of the available safety, efficacy, pharmacokinetic, and pharmacodynamic data obtained from the Phase 1 portion of the study. However, Phase 2a of the study was not opened for enrollment due to changes in the Sponsor's overall clinical development plan.","id":"OG000","title":"Phase 2a: Mezagitamab"}],"populationDescription":"Data was not collected as Phase 2a of the study was not opened for enrollment due to changes in the Sponsor's overall clinical development plan.","reportingStatus":"POSTED","timeFrame":"From the first dose of study drug through 30 days after the last dose (up to approximately 3.7 years)","title":"Phase 2a: Number of Participants Reporting One or More TEAEs","type":"SECONDARY"}